Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 29, 2026, 2:59 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1657–1680 of 26,241 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Cancer Patient Clear all
Completed Phase 1 Interventional

Combination of the Hedgehog Inhibitor, LDE225, With Etoposide and Cisplatin in the First-Line Treatment of Patients With Extensive Stage Small Cell Lung Cancer (ES-SCLC)

NCT01579929
View directory record Official record
Conditions
Lung Cancer
Interventions
LDE225, Etoposide and Cisplatin
Drug
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years and older
Enrollment
19 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2017
U.S. locations
5
States / cities
Basking Ridge, New Jersey • Commack, New York • New York, New York + 2 more
Source: ClinicalTrials.gov public record
Updated Aug 17, 2017 · Synced Oct 29, 2026, 2:59 AM EDT
Recruiting Phase 2 Interventional

A Study of SDX-7320 in Combination With Eribulin for People With Breast Cancer

NCT05570253
View directory record Official record
Conditions
Breast Cancer, Metastatic Triple-Negative Breast Cancer
Interventions
Eribulin, SDX-7320, Placebo
Drug · Other
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years and older
Enrollment
55 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2027
U.S. locations
10
States / cities
Miami, Florida • Atlanta, Georgia • Basking Ridge, New Jersey + 7 more
Source: ClinicalTrials.gov public record
Updated Sep 9, 2026 · Synced Oct 29, 2026, 2:59 AM EDT
Completed Phase 1 Interventional

A Study of the Safety and Activity of the MEK Inhibitor Given Together With the AKT Inhibitor to Patients With Multiple Myeloma or Solid Tumor Cancers

NCT01476137
View directory record Official record
Conditions
Cancer
Interventions
GSK1120212, GSK2110183
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years and older
Enrollment
335 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2013
U.S. locations
2
States / cities
Dallas, Texas • San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Nov 13, 2017 · Synced Oct 29, 2026, 2:59 AM EDT
Completed Phase 2 Interventional Results available

Donor Atorvastatin Treatment in Preventing Severe Acute GVHD After Nonmyeloablative Peripheral Blood Stem Cell Transplant in Patients With Hematological Malignancies

NCT01527045
View directory record Official record
Conditions
Aggressive Non-Hodgkin Lymphoma, Blasts Under 5 Percent of Bone Marrow Nucleated Cells, Chronic Lymphocytic Leukemia, Loss of Chromosome 17p, Myelodysplastic/Myeloproliferative Neoplasm, Non-Hodgkin Lymphoma, Prolymphocytic Leukemia, Recurrent Adult Acute Lymphoblastic Leukemia, Recurrent Adult Acute Myeloid Leukemia, Recurrent Aggressive Adult Non-Hodgkin Lymphoma, Recurrent Childhood Acute Lymphoblastic Leukemia, Recurrent Childhood Acute Myeloid Leukemia, Recurrent Chronic Lymphocytic Leukemia, Recurrent Chronic Myelogenous Leukemia, BCR-ABL1 Positive, Recurrent Diffuse Large B-Cell Lymphoma, Recurrent Hodgkin Lymphoma, Recurrent Mantle Cell Lymphoma, Recurrent Non-Hodgkin Lymphoma, Recurrent Plasma Cell Myeloma, Recurrent Small Lymphocytic Lymphoma, Waldenstrom Macroglobulinemia
Interventions
Atorvastatin Calcium, Cyclosporine, Fludarabine Phosphate, Laboratory Biomarker Analysis, Mycophenolate Mofetil, Nonmyeloablative Allogeneic Hematopoietic Stem Cell Transplantation, Peripheral Blood Stem Cell Transplantation, Total-Body Irradiation
Drug · Other · Procedure + 1 more
Lead sponsor
Fred Hutchinson Cancer Center
Other
Eligibility
Not listed
Enrollment
47 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2019
U.S. locations
2
States / cities
Denver, Colorado • Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Jan 2, 2020 · Synced Oct 29, 2026, 2:59 AM EDT
Not listed Not applicable Interventional Accepts healthy volunteers

Virtual Personalized Exercise Program for Lung Cancer Patients

NCT06540495
View directory record Official record
Conditions
Lung Cancer
Interventions
Salaso Virtual Exercise Program
Behavioral
Lead sponsor
Northwell Health
Other
Eligibility
18 Years and older
Enrollment
60 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2025
U.S. locations
1
States / cities
New Hyde Park, New York
Source: ClinicalTrials.gov public record
Updated Aug 6, 2024 · Synced Oct 29, 2026, 2:59 AM EDT
Recruiting Phase 2 Interventional

Osimertinib Alone or With Chemotherapy for EGFR-Mutant Lung Cancers

NCT04410796
View directory record Official record
Conditions
Metastatic Non-small Cell Lung Cancer
Interventions
Osimertinib, Carboplatin, Pemetrexed
Drug
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years and older
Enrollment
571 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2027
U.S. locations
18
States / cities
Sacramento, California • San Francisco, California • Tampa, Florida + 13 more
Source: ClinicalTrials.gov public record
Updated Sep 11, 2026 · Synced Oct 29, 2026, 2:59 AM EDT
Completed Phase 2 Interventional

Chemotherapy and Radiation Therapy in Treating Patients With Stomach Cancer

NCT00003862
View directory record Official record
Conditions
Gastric Cancer
Interventions
cisplatin, fluorouracil, leucovorin calcium, paclitaxel, conventional surgery, neoadjuvant therapy, radiation therapy
Drug · Procedure · Radiation
Lead sponsor
Radiation Therapy Oncology Group
Network
Eligibility
0 Years to 120 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 1999
U.S. locations
55
States / cities
Anchorage, Alaska • Phoenix, Arizona • Concord, California + 46 more
Source: ClinicalTrials.gov public record
Updated Oct 19, 2020 · Synced Oct 29, 2026, 2:59 AM EDT
Completed Phase 2 Interventional

SU5416 in Treating Patients With Advanced, Metastatic, or Recurrent Soft Tissue Sarcomas

NCT00005862
View directory record Official record
Conditions
Gastrointestinal Stromal Tumor, Sarcoma
Interventions
semaxanib
Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2000
U.S. locations
2
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Feb 11, 2013 · Synced Oct 29, 2026, 2:59 AM EDT
Active, not recruiting No phase listed Observational

A Study of Ado-trastuzumab Emtansine (T-DM1)-Induced Peripheral Neuropathy in HER2-positive Breast Cancer Patients

NCT05889988
View directory record Official record
Conditions
Breast Neoplasm
Interventions
Not listed
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older
Enrollment
36 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2027
U.S. locations
21
States / cities
Aitkin, Minnesota • Baxter, Minnesota • Brainerd, Minnesota + 17 more
Source: ClinicalTrials.gov public record
Updated Nov 20, 2025 · Synced Oct 29, 2026, 2:59 AM EDT
Completed Phase 1 Interventional

Phase Ib/II Study of Buparlisib Plus Carboplatin or Lomustine in Patients With Recurrent Glioblastoma Multiforme

NCT01934361
View directory record Official record
Conditions
Recurrent Glioblastoma Multiforme
Interventions
buparlisib, carboplatin, lomustine, placebo
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
35 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
5
States / cities
Phoenix, Arizona • Fayetteville, Arkansas • Chicago, Illinois + 2 more
Source: ClinicalTrials.gov public record
Updated Dec 9, 2020 · Synced Oct 29, 2026, 2:59 AM EDT
Recruiting Phase 1 Interventional

Novel ACK1 Inhibitor (R)-9b in Patients With Prostate Cancer

NCT06705686
View directory record Official record
Conditions
Metastatic Castration-resistant Prostate Cancer (CRPC), Metastatic Castration-resistant Prostate Carcinoma
Interventions
(R)-9bMS
Drug
Lead sponsor
TechnoGenesys, Inc.
Industry
Eligibility
18 Years and older · Male only
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
1
States / cities
Madison, Wisconsin
Source: ClinicalTrials.gov public record
Updated Mar 20, 2026 · Synced Oct 29, 2026, 2:59 AM EDT
Withdrawn No phase listed Observational

Impact of Vorinostat on Pruritus Signaling Pathways - Merck Study

NCT01801670
View directory record Official record
Conditions
Pruritus
Interventions
Biopsy, Blood
Procedure
Lead sponsor
Boston University
Other
Eligibility
18 Years to 85 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jan 27, 2015 · Synced Oct 29, 2026, 2:59 AM EDT
Completed Phase 1 Interventional

Vorinostat With Gemcitabine, Busulfan, and Melphalan With Stem Cell Transplant (SCT) in Relapsed or Refractory Lymphoid Malignancies

NCT01421173
View directory record Official record
Conditions
Lymphoma
Interventions
Vorinostat, Gemcitabine, Busulfan, Melphalan, Stem Cell Infusion, Rituximab, G-CSF, Palifermin, Dexamethasone acetate
Drug · Procedure
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
12 Years to 65 Years
Enrollment
78 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2015
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Nov 18, 2015 · Synced Oct 29, 2026, 2:59 AM EDT
Recruiting Phase 2 Interventional

Binimetinib for People With Relapsed/Refractory BRAF Wild Type Hairy Cell Leukemia and Variant

NCT04322383
View directory record Official record
Conditions
Hairy Cell Leukemia
Interventions
binimetinib
Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2028
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Oct 16, 2026 · Synced Oct 29, 2026, 2:59 AM EDT
Active, not recruiting Phase 1 Interventional Results available

PSCA-CAR T Cells in Treating Patients With PSCA+ Metastatic Castration Resistant Prostate Cancer

NCT03873805
View directory record Official record
Conditions
Castration-Resistant Prostate Carcinoma, Metastatic Prostate Carcinoma, Stage IV Prostate Cancer AJCC v8, Stage IVA Prostate Cancer AJCC v8, Stage IVB Prostate Cancer AJCC v8
Interventions
Autologous Anti-PSCA-CAR-4-1BB/TCRzeta-CD19t-expressing T-lymphocytes, Cyclophosphamide, Fludarabine, Fludarabine Phosphate
Biological · Drug
Lead sponsor
City of Hope Medical Center
Other
Eligibility
18 Years and older · Male only
Enrollment
14 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2027
U.S. locations
1
States / cities
Duarte, California
Source: ClinicalTrials.gov public record
Updated Jun 2, 2026 · Synced Oct 29, 2026, 2:59 AM EDT
Completed Phase 2 Interventional Results available

Epirubicin, Oxaliplatin and Fluorouracil (EOF) in Cancer of the Esophagus, Gastroesophageal Junction, or Stomach

NCT00601705
View directory record Official record
Conditions
Esophageal Cancer, Gastric Cancer
Interventions
cisplatin, epirubicin hydrochloride, fluorouracil, oxaliplatin, adjuvant therapy, neoadjuvant therapy
Drug · Procedure
Lead sponsor
Case Comprehensive Cancer Center
Other
Eligibility
18 Years and older
Enrollment
61 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2015
U.S. locations
1
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Apr 30, 2019 · Synced Oct 29, 2026, 2:59 AM EDT
Not listed Phase 1Phase 2 Interventional

Rhenium Re 188 P2045 in Patients With Lung Cancer Who Have Received or Refused to Receive Prior Chemotherapy

NCT00100256
View directory record Official record
Conditions
Lung Neoplasms, Carcinoma, Non-Small-Cell Lung, Carcinoma, Small Cell, Neoplasm Recurrence, Local
Interventions
Rhenium (Re 188 P2045, BAY86-5284)
Drug
Lead sponsor
Andarix Pharmaceuticals
Industry
Eligibility
21 Years and older
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2025
U.S. locations
2
States / cities
Iowa City, Iowa • Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Nov 7, 2022 · Synced Oct 29, 2026, 2:59 AM EDT
Recruiting Phase 1Phase 2 Interventional

Safety and Efficacy of BMS-986504 in Unresectable Malignant Peripheral Nerve Sheath Tumor

NCT07549022
View directory record Official record
Conditions
Malignant Peripheral Nerve Sheath Tumors, MPNST
Interventions
BMS-986504
Drug
Lead sponsor
Ankit Mangla, MD
Other
Eligibility
12 Years and older
Enrollment
17 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
1
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Aug 11, 2026 · Synced Oct 29, 2026, 2:59 AM EDT
Terminated Phase 3 Interventional

Vapreotide in Treating Patients Undergoing Elective Pancreatic Resection

NCT00014651
View directory record Official record
Conditions
Pancreatic Cancer, Perioperative/Postoperative Complications
Interventions
vapreotide, conventional surgery
Drug · Procedure
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years to 90 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001 – 2002
U.S. locations
18
States / cities
Birmingham, Alabama • Tampa, Florida • Chicago, Illinois + 13 more
Source: ClinicalTrials.gov public record
Updated Aug 10, 2010 · Synced Oct 29, 2026, 2:59 AM EDT
Completed Phase 2 Interventional Results available

Chemotherapy, Total-Body Irradiation, Rituximab, and Donor Stem Cell Transplant in Treating Patients With B-Cell Non-Hodgkin's Lymphoma or Chronic Lymphocytic Leukemia

NCT00425802
View directory record Official record
Conditions
Leukemia, Lymphoma
Interventions
anti-thymocyte globulin, filgrastim, graft-versus-tumor induction therapy, rituximab, cyclophosphamide, cyclosporine, fludarabine phosphate, mycophenolate mofetil, nonmyeloablative allogeneic hematopoietic stem cell transplantation, total-body irradiation
Biological · Drug · Procedure + 1 more
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years to 70 Years
Enrollment
61 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2016
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Oct 31, 2017 · Synced Oct 29, 2026, 2:59 AM EDT
Completed Phase 2 Interventional

Pilot Protocol for the Treatment of Patients With Small Non-Cleaved and Diffuse Large Cell Lymphomas

NCT00001237
View directory record Official record
Conditions
Burkitt Lymphoma, Lymphoma, Large-Cell, Diffuse, Lymphoma, Small Noncleaved-Cell
Interventions
granulocyte-macrophage colony stimulating factor (GM-CSF)
Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
Not listed
Enrollment
120 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1989 – 2000
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Mar 4, 2008 · Synced Oct 29, 2026, 2:59 AM EDT
Terminated Phase 4 Interventional

Study to Evaluate the Effect of Age (Geriatric) and Kidney Function on the Safety, Efficacy and Pharmacokinetics of OctreoScan in Patients Who Have New or Recurrent Tumors

NCT00944372
View directory record Official record
Conditions
Solid Tumors
Interventions
Indium In-111 pentetreotide
Drug
Lead sponsor
Mallinckrodt
Industry
Eligibility
18 Years and older
Enrollment
150 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2005
U.S. locations
4
States / cities
Miami, Florida • Iowa City, Iowa • New Orleans, Louisiana + 1 more
Source: ClinicalTrials.gov public record
Updated Sep 9, 2016 · Synced Oct 29, 2026, 2:59 AM EDT
Active, not recruiting Phase 2 Interventional

A Study of Pembrolizumab With Carboplatin and Gemcitabine in Patients With Metastatic Triple Negative Breast Cancer

NCT02755272
View directory record Official record
Conditions
Carcinoma Breast Stage IV
Interventions
Pembrolizumab, Carboplatin, Gemcitabine
Drug
Lead sponsor
Fox Chase Cancer Center
Other
Eligibility
18 Years and older · Female only
Enrollment
87 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2026
U.S. locations
6
States / cities
Indianapolis, Indiana • St Louis, Missouri • The Bronx, New York + 3 more
Source: ClinicalTrials.gov public record
Updated Jul 4, 2025 · Synced Oct 29, 2026, 2:59 AM EDT
Completed Phase 1Phase 2 Interventional Results available

ONTAK® in Treating Patients With Advanced Breast Cancer That Did Not Respond to Previous Treatment

NCT00425672
View directory record Official record
Conditions
Male Breast Cancer, Recurrent Breast Cancer, Stage IIIA Breast Cancer, Stage IIIB Breast Cancer, Stage IIIC Breast Cancer, Stage IV Breast Cancer
Interventions
ONTAK, flow cytometry, immunohistochemistry staining method, enzyme-linked immunosorbent assay, laboratory biomarker analysis, protein expression analysis
Biological · Other · Genetic
Lead sponsor
University of Washington
Other
Eligibility
18 Years and older
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2005
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Dec 5, 2018 · Synced Oct 29, 2026, 2:59 AM EDT